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MYCN activation is a hallmark of advanced neuroblastoma (NB) and a known master reg-
ulator of metabolic reprogramming, favoring NB adaptation to its microenvironment. We
found that the expression of the main regulators of the molecular clock loops is profoundly
disrupted in MYCN-amplified NB patients, and this disruption independently predicts poor
clinical outcome. MYCN induces the expression of clock repressors and downregulates the
one of clock activators by directly binding to their promoters. Ultimately, MYCN attenuates
the molecular clock by suppressing BMAL1 expression and oscillation, thereby promoting cell
survival. Reestablishment of the activity of the clock activator RORα via its genetic over-
expression and its stimulation through the agonist SR1078, restores BMAL1 expression and
oscillation, effectively blocks MYCN-mediated tumor growth and de novo lipogenesis, and
sensitizes NB tumors to conventional chemotherapy. In conclusion, reactivation of RORα
could serve as a therapeutic strategy for MYCN-amplified NBs by blocking the dysregulation
of molecular clock and cell metabolism mediated by MYCN.
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Oncogenic expression of the MYC family members (e.g.,MYC and MYCN) drives many human cancers;1 how-ever, strategies aiming at chemically disrupting their
functions have proven difficult to develop. The MYCN oncogene
is amplified in almost half of all high-risk neuroblastomas (NBs)
and is the primary oncogene driving this malignancy2. Over-
expressed MYCN causes spontaneous, high-penetrance NB in
mice, originating from neuroblastic precursor cells3. In tumors
with activated MYC or MYCN, the high demand for growth and
biomass accumulation required for tumor progression is achieved
by metabolic reprogramming4. MYC drives several metabolic
pathways associated with cell growth, including increased
glucose5 and glutamine uptake6, stimulation of mitochondrial
biogenesis7 and nucleotide synthesis8, and enhanced de novo
lipid synthesis9. In particular, MYC directly activates the
expression of lipogenic enzymes (e.g., ACACA, FASN, and
SCD1), promoting de novo fatty acid (FA) synthesis from
citrate10. In addition, MYC interacts with the related transcrip-
tional regulator MondoA to control SREBP1-dependent lipid
biosynthesis11. However, far less is known about MYCN regula-
tion of cell metabolism. MYCN loss of function suppresses FA β-
oxidation and leads to lipid droplet accumulation in NB cells12,
suggesting that aggressive NBs require FA as an energy source.
Cellular metabolism and circadian rhythm intimately
crosstalk13, and MYC regulates rhythmic cell metabolism14.
Moreover, genetic ablation of clock genes enhances glucose and
glutamine consumption in vivo15. The core molecular clock is
composed of the heterodimer CLOCK/BMAL1, which activates
transcription of the PER and CRY genes via binding at specific E-
box sequences. In turn, PER1/2 and CRY1/2 suppress CLOCK/
BMAL116. This transcriptional feedback loop ensures a 24-h
rhythm. Retinoic acid receptor-related orphan receptor alpha
(RORα) and REV-ERBα (also known as nuclear receptor sub-
family 1, group D member 1, NR1D1) are the two major reg-
ulators of both expression and oscillation of the clock central
component BMAL1 (ARNTL) and compete for the ROR response
element (RORE) within the BMAL1 promoter17,18. RORα acti-
vates, whereas REV-ERBα suppresses BMAL1 transcription.
MYC and MYCN have been shown to directly induce REV-ERBα
expression, dampening BMAL1 expression and oscillation14. In
addition, MYC/Myc-interacting zinc-finger protein-1 (MIZ1)
complexes are recruited to non-E-box sites in the BMAL1 and
CLOCK promoters independently of REV-ERB19. However,
MYCN regulation of the molecular clock and its effects on tumor
phenotype remain largely unknown. The clock activator RORα
has been identified as a putative tumor suppressor and is
repressed in many cancer types20–23. Mechanistically, RORα acts
by inducing SEMA3F20 and p53 signaling24 and suppressing
Wnt/βcatenin signaling25. Similarly, BMAL1 is epigenetically
inactivated in hematologic malignancies26, and ectopic expression
enhances sensitivity to chemotherapy27 and reduces clonogenicity
of NB cells14, further supporting its potential tumor-
suppressive role.
RORs and REV-ERBs are known as orphan nuclear receptors;
however, the subsequent identification of their endogenous
ligands28,29 led to the development of synthetic ligands targeting
these receptors. Because the clock components can affect
tumorigenesis, pharmacological modulation of the circadian clock
is emerging as a promising approach for therapeutic intervention.
Recent reports found two REV-ERBs agonists (SR9009 and
SR9011) were lethal to cancer cells by targeting de novo lipo-
genesis and autophagy30. These clock-modulating compounds are
also active against metabolic diseases, including obesity and
diabetes18,31. The synthetic ligand SR1078 functions as a RORα/γ
agonist29 and selectively binds to the ligand-binding domain of
RORα/γ receptors, inducing conformational changes resulting in
recruitment of co-activators and stimulation of transcription29. In
this study, we asked whether dysregulation of the MYCN-
operated clock had functional significance and whether restoring
the positive arm of the clock would interfere with that dysregu-
lation, opposing MYCN-driven oncogenesis. Mechanistically, we
have shown that MYCN attenuates the clock in NB by down-
regulating clock activators and inducing clock repressors.
Restoration of the molecular clock reestablishes cellular lipid
metabolism and efficiently blocks NB tumor growth.
Results
Clock gene expression is altered in MYCN-amplified patients
and predicts poor clinical outcomes. To establish the potential
clinical relevance of MYCN regulation of the clock, we examined
how the expression of the main clock component (BMAL1) and
its activator (RORα) and repressor (REV-ERBα) related to clinical
outcome and MYCN amplification in human NB primary
tumors. We used transcriptomic data from three patient cohorts:
Kocak (n= 649, GEO: GSE45547, patient cohort 1), Versteeg
(n= 88, GEO: GSE16476 88/122, patient cohort 2), and NB
Research Consortium (NRC; n= 283, GEO: GSE85047, patient
cohort 3) (R2: genomics analysis and visualization platform,
http://r2.amc.nl). Kaplan–Meier analysis in cohort 1 revealed that
high RORα and BMAL1 (ARNTL) expression is strongly asso-
ciated with a favorable clinical outcome and stage, while high
REV-ERBα (NR1D1) expression correlates with a poor outcome
and stage (Fig. 1). These findings were validated across multiple
patient cohorts (Supplementary Fig. 1a, patient cohort 2) and
mark the positive arm of the clock as a potential tumor sup-
pressor. Notably, the expression of both RORα and BMAL1 is
strongly repressed in MYCN-amplified (MNA) NB (cohort 1,
Fig. 1; cohort 2, Supplementary Fig. 1a), and this correlates with
poor overall (OS) and progression-free survival (PFS) in all
patient cohorts (Fig. 1 and Supplementary Fig. 1). This associa-
tion is retained when the analysis is restricted to stage 3 and 4
patients (Supplementary Fig. 1b, c). Conversely, REV-ERBα
expression is significantly higher in MNA NB (cohort 1, Fig. 1;
cohort 2, Supplementary Fig. 1a). Notably, we found that RORα
expression predicts outcome independently of current prognostic
factors, including age at diagnosis, International Neuroblastoma
Staging System (INSS) stage, and MYCN status (Supplementary
Table 1). Collectively, our data define the low expression of the
positive arm of the clock (RORα-BMAL1) as an unfavorable
prognostic marker in NB.
MYCN disrupts the molecular clock by direct binding to clock
gene promoters. Due to the significant association between cir-
cadian genes and MYCN expression in patients, we next exam-
ined whether MYCN could alter clock gene expression. To test
this hypothesis, we conditionally overexpressed MYCN in
MYCN3 (Tet-ON) cells and conditionally silenced MYCN in
LAN5 MNA cells (LAN5 ShMYCN). Ectopic MYCN expression
resulted in significant upregulation of the circadian repressor
REV-ERBα, and downregulation of the circadian activators RORα
and BMAL1. However, depletion of MYCN completely restored
their expression levels (Fig. 2a). We then used a human NB line
SK-N-AS that lacks amplification of MYCN and stably expresses
inducible wild-type MYCN-ERTM (estrogen receptor tamoxifen
mutant). When stimulated with 4-hydroxytamoxifen (4OHT),
MYCN-ER translocates into the nucleus and upregulates MYCN
targets14. MYCN transcriptional activation led to significant
upregulation of REV-ERBα and downregulation of RORα and
BMAL1 both at mRNA and protein levels (Fig. 2b). As a control,
we demonstrated that both doxycycline (DOX) and 4OHT do not
alter clock gene expression (DBP, BMAL1, and PER2) in parental
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LAN5 and SK-N-AS cells (Supplementary Fig. 2). Collectively,
these data support a role for MYCN in altering circadian gene
expression, and specifically suppressing the positive arm of the
clock.
We then asked whether MYCN could also disrupt circadian
rhythmicity. We subjected DOX-induced MYCN3 and LAN5
ShMYCN cells to real-time luminescence analysis using a
previously established Per2-luc adenovirus reporter32 and found
that MYCN induction also impairs the circadian oscillation of
PER2 by both lengthening the circadian period and reducing the
circadian amplitude (Supplementary Fig. 3). These results are
consistent with previously reported impaired BMAL1 oscillation
in MYC overexpressing cell lines14.
To address the mechanism of MYCN regulation of the clock,
we performed MYCN chromatin immunoprecipitation (ChIP)-
qPCR analysis in both MNA cells and MYCN Tet-OFF (Tet-21/
N) cells, in which MYCN is turned off upon DOX treatment
(Fig. 2c and Supplementary Fig. 4). We found significant
enrichment of MYCN binding to the promoter regions of REV-
ERBα, RORα (transcript variants 1 and 4), and BMAL1 in both
MNA cell lines. Moreover, turning off MYCN fully abrogates
MYCN binding (Fig. 2c). These findings suggest that MYCN
directly attenuates the clock by repressing the clock activators
RORα and BMAL1, and inducing the clock repressor REV-
ERBα. Because MYCN induces transcriptional repression by
indirectly binding to DNA in part through interactions with
MIZ133, we performed MYCN ChIP-qPCR analysis in LAN5
cells upon genetic depletion of MIZ1 (LAN5 ShMIZ1) to
determine whether loss of MIZ1 altered MYCN occupancy at
clock activators genes. Effective knockdown of MIZ1 (Supple-
mentary Fig. 5a, b) significantly reduces MYCN binding at
the promoter regions of BMAL1 and RORα (Supplementary
Fig. 5c, d), suggesting that MYCN repression of the clock
requires MIZ1.
RORα activity rescues MYCN-mediated repression of BMAL1
expression and oscillation. Synthetic ligands for RORs have been
recently characterized, including the RORα/γ agonist SR107834.
Unlike most family members, the RORs recognize and bind as
monomers to specific sequences of DNA (ROR response ele-
ments, RORE) in the regulatory region of the target genes. When
bound to these elements, they constitutively recruit co-activators
resulting in continual transcriptional activation35. To test whether
RORα signaling is active in NB cells, we used two approaches:
Fig. 1 Clock gene expression is altered in primary NB tumor samples and correlates with poor clinical outcomes. Kaplan-Meier analysis of overall
survival (OS) in patient cohort 1 (Kocak n= 476, GEO: GSE45547). Graphs depict p-values corrected for multiple testing (Bonferroni correction) of cutoff
levels for RORα, BMAL1, and REV-ERBα. Correlations between clock gene expression, INSS stages, and MYCN amplification status are shown. MNA=
MYCN-amplified; S1–4S= stage1-4S; 476 of the 649 samples were annotated with survival data. The box plot is defined by two lines at the 25th and 75th
percentile. A line is drawn inside the box at the 50th percentile.
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RORα pharmacological activation (via the agonist SR1078) and
RORα genetic overexpression. Two MNA cell lines (LAN5 and
SK-N-BE(2)-C) were treated with SR1078 and the mRNA
expression of RORα target genes containing a RORE in their
promoters (G6Pase, FGF-21, and BMAL1)36 was determined.
SR1078 effectively activates target gene transcription in both cell
lines (Fig. 3a). We next examined whether genetic overexpression
of RORα could activate downstream signaling as well. To ecto-
pically express RORα, we inserted a lentiviral DOX-inducible
vector containing the sequence of RORα (isoform 1) into MNA
LAN5 cells because these cells showed relatively low RORα
expression compared to other cell lines tested. Conditional RORα
overexpression resulted in robust transcriptional activation of its
target genes34 (Fig. 3a). Furthermore, SR1078 and the genetic
MYCN 
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overexpression of RORα efficiently induced BMAL1 protein
expression in both systems (Fig. 3b).
We then asked whether SR1078 and RORα overexpression
could rescue MYCN-mediated repression of BMAL1 expression
and oscillation. For this purpose, we employed two inducible
MYCN cell systems: MYCN3 (Tet-ON) and SK-N-AS MYCN-ER
cells. As expected, all known and identified MYCN-target genes
(ODC1, REV-ERBα, DKC1, RORα, and BMAL1) were signifi-
cantly induced or repressed upon turning on MYCN. Notably,
BMAL1 mRNA and protein levels were repressed in both systems
upon MYCN activation. However, SR1078 treatment and RORα
genetic overexpression were both able to completely rescue
BMAL1 mRNA and protein levels (Fig. 3c). Moreover, active
MYCN-ER (MYCN-ON) greatly impaired circadian oscillation of
BMAL1 in SK-N-AS MYCN-ER cells. However, overexpression of
RORα was capable of both restoring BMAL1 expression, and also
fully rescuing its circadian oscillation (Fig. 3d). Similarly, turning
ON RORα highly enhanced BMAL1 oscillation in MNA cells
(Supplementary Fig. 6). Collectively, these data indicate that
RORα activity effectively counteracts MYCN-mediated repression
of BMAL1 expression and oscillation.
MYC and other cell cycle regulators have been shown to be
clock-regulated37, suggesting that multiple feedback loops exist
between MYC and the components of the molecular clock. Thus,
we asked whether restoration of the clock could alter c-MYC and
MYCN expression. MYCN protein stabilization was notably
decreased by ROR agonist SR1078 in MNA cells (LAN5 and SK-
N-BE(2)C); however, no changes in c-MYC protein levels were
detected in non-MNA c-MYC overexpressing cells (SH-SY5Y)
(Supplementary Fig. 7), suggesting that this clock-mediated
regulation is MYCN-dependent.
Restoration of BMAL1 via RORα activation inhibits cell
growth and lipogenic gene expression. Because MYCN repres-
sion of the clock correlates with poor clinical outcomes, we then
asked whether restoration of the clock via activation of RORα
could have a functional significance and alter NB cell phenotype.
SR1078 inhibits cell growth in both MNA and non-MNA cell
lines. However, this effect is greater in MNA compared to non-
MNA cells. Similarly, MNA cells show higher caspase-mediated
apoptosis following SR1078 treatment (Fig. 4a). Genetic over-
expression of RORα (RORα Tet-ON) also profoundly restricts cell
growth and induces cell cycle arrest (Fig. 4b and Supplementary
Fig. 8). However, depletion of BMAL1 (Supplementary Fig. 9)
promotes cell growth and almost completely rescues the block in
cell viability and the apoptosis induced both by SR1078 and
RORα overexpression (Fig. 4c), suggesting that the anti-tumor
activity of RORα is dependent on BMAL1. Because cell viability
assays such as MTT and CCK-8 sense metabolic processes, we
used cell counting as an alternative method and confirmed the
same changes in cell proliferation (Supplementary Fig. 10). In
addition, because SR1078 can stabilize p5324, we tested whether
this also occurs in NB. We detected no changes in p53 protein
levels upon SR1078 treatment in multiple MNA lines. Moreover,
genetic depletion of p53 did not affect the response to SR1078
(Supplementary Fig. 11), suggesting that SR1078 alters cell via-
bility in a p53-independent manner.
To further elucidate the molecular mechanisms by which
SR1078 impairs cell survival, we performed RNA-sequencing
analysis in LAN5 cells with and without SR1078 treatment for 8
h. A total of 712 genes were differentially regulated (p < 0.05): 459
downregulated and 253 upregulated (Fig. 4d). Reactome pathway
enrichment analysis showed that the most downregulated
biological processes were cholesterol biosynthesis and regulation
by SREBP (adjusted p= 2.44E−09), metabolism of lipids and
lipoproteins (adjusted p= 1.01E−03), and tubulin folding
(adjusted p= 1.39E−03), while amino acid transporters (adjusted
p= 9.13E−04) were the most upregulated (Fig. 4d and Supple-
mentary Data 1), suggesting that restoration of the clock alters
cell metabolism. Overall, 34 out of the 459 SR1078-
downregulated genes belonged to the top enriched lipid pathways
(cholesterol biosynthesis and regulation by SREBP, and metabo-
lism of lipids and lipoproteins, in blue, Supplementary Fig. 12a).
We further selected ten genes specifically involved in cholesterol
synthesis (IDI-1, HMGR, HMGCS1, and MVK2) and FA
metabolism (FABP3, FABP5, ELOVL2, ELOVL6, ACSL3, and
SCD1) and validated their expression after SR1078 treatment by
q-PCR in MNA cells. Both these gene sets were significantly
downregulated by SR1078 in LAN5 cells (Supplementary
Fig. 12b). Cell metabolism is tightly controlled by the molecular
clock38 as both metabolites and metabolic gene expression are
subject to circadian oscillations39. Altogether, these data indicate
that activation of RORα inhibits NB cell survival by restoring
BMAL1 expression and constraining lipogenic gene expression.
Activation of RORα restores BMAL1 and blocks NB tumor
growth by inhibiting lipid metabolism. Our patient and in vitro
data both suggest that clock activators RORα and BMAL1 are
downregulated in MNA NB. These data also suggest that acti-
vation of RORα restricts cell survival. We, therefore, examined
the in vivo anti-tumor activity of restoring RORα function via
SR1078 and genetic overexpression. For this purpose, we used an
orthotopic NB mouse model and generated MNA xenografts by
implanting MNA cells under the renal capsule of nude mice. This
model faithfully recapitulates the aggressive and highly vascular
phenotype of primary NB40. LAN5 cells were engrafted and
SR1078 treatment was initiated 2 weeks after implantation.
Vehicle control and SR1078 (15 mg/kg) were given i.p. daily for
14 days, and the effect on tumor growth was compared between
groups at the end of the treatment. SR1078 treatment resulted in
significant inhibition of tumor growth (p= 0.02). The ability of
SR1078 to block tumor growth was confirmed in a second MNA
xenograft model, derived from MNA IMR32 cells (p= 0.0004).
Notably, SR1078 anti-tumor activity was associated with the
Fig. 2 MYCN directly binds to clock gene promoters and downregulates the positive arm of the clock. a Left panel: MYCN protein expression in MYCN3
(MYCN Tet-ON) and LAN5 ShMYCN cells after DOX (1 µg/ml) induction for 48 and 72 h, respectively. Protein expression was analyzed by densitometry
(Image J v1.42q). CypB served as a loading control and MYCN/CypB ratio was determined (n= 2 independent experiments). Right panel: mRNA levels of
MYCN, REV-ERBα, RORα, and BMAL1 in MYCN3 (MYCN Tet-ON) and LAN5 ShMYCN cells following DOX induction for 48 and 72 h, respectively. Data are
mean ± SD (n= 3; ****p < 0.0001; two-tailed unpaired t-test). b mRNA and protein expression of REV-ERBα, RORα, and BMAL1 in SK-N-AS MYCN-ER cells
with and without 4OHT (1 µM) for 0, 8, 16, 24, and 48 h. mRNA data are mean ± SD (n= 3; ****p < 0.0001; two-tailed unpaired t-test). Protein expression
data were analyzed by densitometry (Image J v1.42q). CypB served as loading control and REV-ERBα/RORα/BMAL1/CypB ratios were determined (n= 2).
REV-ERBα and RORα were run on the same gel. c MYCN ChIP-qPCR assays in LAN5 and Tet-21/N (MYCN Tet-OFF) cells following tetracycline treatment
(2 μg/ml for 48 h). Input (white bars) and MYCN IP (blue bars) samples were analyzed by q-PCR using specific primers for REV-ERBα, RORα, BMAL1, and
RORc (Supplementary Table 3). Data are mean ± SD (n= 3; ****p < 0.0001; two-way ANOVA with Dunnett’s multiple comparisons test). FC fold change,
FE fold enrichment.
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restoration of BMAL1 protein levels in the xenograft tumors
(Fig. 5a). However, SR1078 was not able to block tumor growth in
a non-MNA xenograft model of SK-N-AS cells (p= 0.5116)
(Fig. 5b), suggesting that the tumor-suppressive function of
RORα activation is MYCN-dependent. The general health con-
ditions of the mice and their body weights were recorded weekly
throughout the studies and no apparent signs of toxicity related to
SR1078 treatment were noted (Supplementary Fig. 13). We then
engrafted LAN5 RORα Tet-ON cells and evaluated their ability to
grow in nude mice with and without DOX treatment to induce
RORα overexpression. Overexpression of RORα significantly
blocked tumor growth (p= 0.013), and DOX-induced tumors
also showed higher BMAL1 protein levels (Fig. 5c). In addition,
compared to control tumors, tumor cell proliferation was
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d SK-N-AS MYCN-ER RORα Tet-ON
CycID BH.Q ADJ.P PER LAG AMP
CTRL 0.0228 0.0114 30 0 2.41502
4OHT 0.00348 0.00057 24 6 0.23021
DOX 0.00348 0.00131 30 0 8.43777
COM 0.00348 0.00131 30 0 8.43777
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significantly lower in tumors that were both treated with SR1078
and overexpressing RORα (p < 0.0001 and p= 0.0012, respec-
tively). Although SR1078 induced a robust apoptotic response in
the treated tumors compared to controls (p= 0.0358), only a mild
effect on cell apoptosis was observed in RORα-overexpressing
tumors (Supplementary Fig. 14). Collectively, our data suggest
that restoration of BMAL1 is tumor suppressive in NB.
The RNA-seq data indicated that SR1078 inhibits NB cell
survival in part by suppressing genes involved in lipid metabolism
(Fig. 4d). To determine whether SR1078 suppresses tumor growth
by perturbing lipid metabolism, we performed lipidomics analysis
in control (n= 10) and SR1078-treated (n= 8) LAN5 tumors.
Supporting our RNA-seq data, we found that intratumoral levels
of glycerolipids, such as triglycerides (TGs) and their precursors
diglycerides (DGs) were significantly reduced by SR1078 (FDR <
0.25; Fig. 5d and Supplementary Data 2), suggesting that
activation of RORα effectively inhibits in vivo lipogenesis. In
contrast, the intratumoral cholesterol esters were increased by
SR1078 (Supplementary Fig. 15). This finding challenges our
RNA-seq data in which cholesterol biosynthesis genes were
suppressed by SR1078, suggesting a potential compensatory
upregulation of cholesterol uptake in these tumors. Because FAs
are required for DG and TG synthesis, we further determined
what changes in FA composition were induced by SR1078 using
liquid chromatography-mass spectrometry (LC-MS)-based FA
profiling. Notably, SR1078 significantly reduces the levels of
intratumoral FAs including C12:0, C16:0, C18:1, and C20:3, all of
which serve as side chains of the reduced DG and TG groups
(Fig. 5e and Supplementary Table 2). Altogether, these data
suggest that SR1078 blocks tumor growth by inhibiting FA
metabolism and glycerolipid synthesis.
Activation of RORα opposes MYCN-driven lipogenesis. Recent
reports have emphasized the role of MYC in reprogramming lipid
metabolism to enhance tumorigenesis41. MYC induces SREBP1c-
dependent de novo FA synthesis and directly activates the tran-
scription of key lipogenic enzymes to support cancer growth42.
On the other hand, RORs are also key regulators of lipid meta-
bolism with tissue-dependent effects35. Nobiletin (a natural fla-
vone)-mediated activation of RORα/γ protects against metabolic
syndrome, suggesting a role in metabolic regulation43. Moreover,
our RNA-seq and in vivo lipidomics data suggest that SR1078
acts by inhibiting cell metabolic processes, in particular lipid
biosynthesis. Unlike normal cells, cancer cells highly depend on
de novo lipogenesis44. We first asked whether the main lipogenic
genes (Acetyl-CoA Carboxylase Alpha (ACACA), FA synthase
(FASN), and stearoyl-CoA desaturase 1 (SCD1)) behave as direct
MYCN targets. ChIP-qPCR analyses confirmed a significant
enrichment of MYCN binding at the promoter regions of all
lipogenic genes (Fig. 6a and Supplementary Fig. 16). We then
tested whether activation of RORα could repress MYCN-driven
lipogenic gene expression. The mRNA levels of the lipogenic
genes were all significantly repressed following SR1078 treatment.
However, depletion of BMAL1 completely reestablished their
levels, suggesting that SR1078 inhibition of lipogenic gene
expression is mediated by BMAL1 (Fig. 6b). This observation was
further supported by BMAL1 ChIP-qPCR analysis in SK-N-AS
MYCN-ER RORα cells, which confirmed reduced BMAL1 bind-
ing at the promoters of all three lipogenic enzymes upon acti-
vation of MYCN and increased binding upon overexpression of
RORα (Fig. 6c), suggesting that MYCN and BMAL1 may com-
pete for binding at these loci. Moreover, SR1078 treatment res-
cued the induction of lipogenic gene expression mediated by
MYCN in MYCN3 (Tet-ON) cells (Fig. 6d).
To further determine the effects of SR1078 on MYCN-
induced de novo lipogenesis and desaturation activity, stable
isotope labeling and gas chromatography-mass spectrometry
(GC-MS) were employed for FA determination. Turning on
MYCN expression significantly increases the concentration of
de novo synthesized C14:0 (myristic acid) and C16:0 (palmitic
acid), and enhances SCD1 activity as indicated by the 13C16-
labeled C16:1 (palmitoleic acid) to 13C16-labeled C16:0 ratio.
However, SR1078 restores these FA levels, suggesting that
activation of RORα efficiently blocks MYCN-mediated de novo
FA synthesis and desaturation (Fig. 6e). Because the most
profound effect of SR1078 was on SCD1 expression and
activity, we next examined how SCD1 expression relates to NB
clinical outcome. SCD1 expression is strongly associated with
poor clinical outcomes and MYCN amplification (Fig. 6f).
Moreover, ChIP-qPCR analyses in MYCN Tet-OFF cells
confirmed a significant enrichment of MYCN binding at the
SCD1 promoter, which is fully abrogated upon turning off
MYCN (Fig. 6g), suggesting that MYCN directly transcription-
ally induces SCD1 to promote lipogenesis. Selected FAs (e.g.,
oleic acid), the main product of SCD1, have been shown to
rescue cell viability in cancer cells treated with FA synthesis
inhibitors (e.g., TOFA)36. We found that culture media
supplemented with oleic acid partially rescues the viability of
MNA cells treated with SR1078 (Fig. 6h), suggesting that
SR1078 targets MYCN-mediated SCD1 activity.
Activation of RORα sensitizes NB tumors to conventional
chemotherapy. We hypothesized that activation of RORα, by
restoring the molecular clock and cell metabolism, could sensitize
NB to conventional therapy. To investigate whether SR1078 alters
the sensitivity of NB cells to conventional therapies such as
Fig. 3 RORα activity rescues MYCN-mediated repression of BMAL1 expression and oscillation. a mRNA expression of RORα target genes (BMAL1,
G6Pase, and FGF-21) in MNA LAN5 and SK-N-BE(2)-C cells treated with SR1078 (10 µM for 24 h), and LAN5 RORα Tet-ON cells cultured with (RORα-ON)
and without (RORα-OFF) DOX (2 µg/ml) for 48 h. Data are mean ± SD (n= 3; ****p < 0.0001; two-tailed unpaired t-test). b Upper panel: BMAL1 protein
expression in LAN5 and SK-N-BE(2)-C cells treated with SR1078. Lower panel: RORα and BMAL1 protein expression in LAN5 RORα Tet-ON cells cultured
with (RORα-ON) and without (RORα-OFF) DOX (2 µg/ml) for 24 h. Data were analyzed by densitometry (Image J v1.42). CypB served as a loading control
and BMAL1/RORα/CypB ratios were determined (n= 2). c Upper panel: mRNA expression of MYCN target genes in MYCN3 cells treated with (MYCN-
ON) and without (MYCN-OFF) DOX (1 µg/ml) for 48 h, and in SK-N-AS MYCN-ER cells treated with and without 4OHT (1 µM) for 48 h. Data are mean ±
SD (n= 3; ****p < 0.0001; two-tailed unpaired t-test). Lower panel: BMAL1 mRNA and protein expression in MYCN3 cells under MYCN-OFF, MYCN-ON,
and MYCN-ON + SR1078 (5 µM for 24 h) conditions. BMAL1 mRNA and protein expression in SK-N-AS MYCN-ER RORα Tet-ON cells upon MYCN
activation (4OHT 1 µM for 24 h) with and without RORα overexpression (DOX 2 µg/ml for 24 h). Protein expression data were analyzed by densitometry
(Image J v1.42q) and BMAL1/CypB ratios determined (n= 2). d SK-N-AS MYCN-ER RORα cells were cultured with and without 4OHT (MYCN-ON/OFF),
DOX (RORα-ON/OFF), and 4OHT+DOX for 24 h and then synchronized with 50% horse serum for 2 h. Cells were collected every 6 h from 16 to 64 h
after synchronization. 4-OHT and DOX treatments were applied during and after cell synchronization. BMAL1 mRNA expression was determined by q-PCR
and normalized to 18 S expression. Data are mean ± SEM (n= 2, p < 0.0001 at all conditions and time points by two-way ANOVA with Tukey’s multiple
comparisons test). BMAL1 oscillates at all conditions (p < 0.05) according to the JTK-rhythmicity test. FC fold change.
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etoposide (VP16), MNA cells were exposed to different con-
centrations of SR1078 and VP16 as single agents and in combi-
nation (IC50 doses). VP16 IC50 values were significantly reduced
(10.3, 4.2, and 10.3 fold for LAN5, IMR32, and NGP cells,
respectively) when cells were exposed to the combination therapy
(Fig. 7a). SR1078 IC50 values were also robustly reduced (13.6, 29,
and 40 fold, respectively) when cells were treated with the
combination therapy (Supplementary Fig. 17). Moreover, the
addition of low-dose SR1078 strongly enhanced the cell apoptosis
induced by VP16 in all three cell lines (Fig. 7a). We then tested
the anti-tumor activity of our combination therapy in vivo, using
orthotopic xenografts generated from MNA NGP cells. As
expected, single agents SR1078 and VP16 significantly blocked
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tumors to VP16 (p= 0.0031) (Fig. 7b), suggesting that modula-
tion of the clock could be a viable therapeutic approach.
Discussion
We have shown here that MYCN suppresses the molecular clock
in NB. In turn, restoration of the clock effectively counteracts
MYCN-mediated cell growth and metabolism. MYCN-amplifi-
cation, which occurs in 50% of high-risk NB, distinguishes
tumors with a high relapse rate and poor survival2,45. We found
that MYCN directly activates the clock repressor REV-ERBα
while suppressing the activators RORα and BMAL1. This dysre-
gulation is a powerful NB prognostic marker: low RORα and
BMAL1 expression and high REV-ERBα expression strongly
associated with poor clinical outcomes, independently of other
prognostic factors.
The downregulation of the clock by MYCN is consistent with
previous studies showing that ectopic MYC expression activates
REV-ERBα to dampen BMAL1 expression and oscillation46 and
downregulates core clock gene expression via MIZ119. Indeed, in
the context of transcriptional repression MYC does not directly
contact DNA but associates with DNA-bound transcription fac-
tors, such as MIZ1 and/or Sp147. Our data show that depletion of
MIZ1 reduces the MYCN binding at the promoter regions of
BMAL1 and RORα, suggesting that MIZ1 mediates MYCN
repression of the clock in NB cells. This is further supported by
the observation that MYCN physically binds the BMAL1 pro-
moter despite the absence of a functional E-box and in the region
where MIZ1 binds. Importantly, we show that MYCN suppresses
the clock activators RORα and BMAL1 to sustain cell prolifera-
tion and rewire cell metabolism, suggesting that this dysregula-
tion has a functional significance and may contribute to NB
oncogenesis. Depending on the context, BMAL1 can function as a
tumor suppressor14 or oncogene48. Interestingly, MYC and
BMAL1 are basic helix-loop-helix DNA-binding transcription
factors, which recognize the same E-box sequences in the reg-
ulatory regions of target genes49,50. Our ChIP-qPCR data revealed
reduced BMAL1 occupancy of target E-box sites in lipogenic
genes, which is rescued by ectopic RORα. Thus, we can speculate
that oncogenic MYCN plays a role in disrupting BMAL1-
controlled transcription and metabolism. RORα and BMAL1 gene
silencing is found in several other cancers, including hematolo-
gical malignancies26. RORs also play important roles in tumor
metabolism and inflammation. Genetic studies have shown that
attenuated RORα leads to various metabolic abnormalities in
mice, including hyperglycemia and glucose intolerance51. More-
over, RORα inhibits inflammation by interfering with NF-kB
signaling52.
These observations prompted us to investigate whether
restoring the clock could counteract the effects of MYCN on cell
growth and metabolism. To restore the core clock component
BMAL1 and clock function, we pharmacologically activated the
circadian activator RORα via SR1078, a synthetic RORα/γ ligand
agonist that selectively binds to the ligand-binding domain of the
receptors promoting the transcription of target genes, such as
BMAL134. Our data indicate that restoration of the molecular
clock is tumor suppressive in NB. Both SR1078 and genetic
overexpression of RORα effectively restore BMAL1 expression
and oscillation, and block tumor growth in MNA, but not in non-
MNA orthotopic xenografts, suggesting that the anti-tumor effect
of SR1078 is MYCN-dependent. Importantly, the anti-tumor
activity of SR1078 and RORα is abolished following depletion of
BMAL1, further supporting that the core clock component
BMAL1 functions as a tumor suppressor in NB. These emerging
connections between clock disruption and oncogenesis suggest
that circadian interventions could be employed for anti-cancer
treatment. Supporting this concept, recent work suggests that
pharmacological agonists of REV-ERBs are selectively lethal to
cancer cells and block glioblastoma (GBM) and GBM stem cell
growth30,48. We further hypothesized that SR1078, by restoring
the molecular clock and cell metabolism, could be used in com-
bination with conventional therapies to reduce toxicity and
enhance chemotherapeutic viability. We find that
SR1078 significantly improves the anti-tumor activity of the
standard-of-care drug etoposide in MNA xenografts, suggesting
that pharmacological modulation of the clock could be explored
in future combination studies.
Metabolic rewiring is a key function of MYC oncogenes.
Although several c-MYC metabolic functions are well char-
acterized, the role of MYCN in metabolic reprogramming is
less defined. MYC, in coordination with SREBP1, controls
lipogenesis, which is required for both initiation and main-
tenance of tumorigenic growth53. Moreover, inhibition of FA
oxidation dampens tumor growth of triple-negative breast
cancers overexpressing MYC54. Interestingly, the activity of
some of these lipogenic enzymes has been previously reported
to be clock-controlled55 and linked to oncogenesis56, suggest-
ing that changes in their circadian activity may affect tumor
growth. We demonstrate here that MYCN directly induces
lipogenic gene expression and lipid intermediates, which are
constrained by SR1078 in a BMAL1-dependent fashion.
Moreover, SR1078 profoundly inhibits lipid metabolism in vivo
by reducing glycerolipids and their FA components. Thus, we
postulate that MYCN-mediated repression of the clock could
induce the unconstrained expression of lipogenic genes and activate
lipid metabolism to support tumor growth. However, restoration of
the clock effectively constrains MYCN-mediated lipogenesis. We
show that MYCN directly binds and upregulates the stearoyl-CoA
desaturase-1 (SCD1), which catalyzes the synthesis of mono-
unsaturated from saturated FA. In turn, activation of RORα blocks
MYCN-induced SCD1 expression and activity. Moreover, supple-
mentation with oleic acid, the major product of SCD1, rescues the
viability of NB cells, confirming that SR1078 functions by blocking
Fig. 4 RORα activation inhibits cell survival via BMAL1 and constrains lipogenic gene expression. a Cell viability (MTT assay) and apoptosis (caspase
3/7 assay) in MNA (LAN5, IMR32) and non-MNA (SH-SY5Y, SK-N-AS) cells following treatment with SR1078 for 24 h (apoptosis) and 72 h (cell
viability). IC50 values are shown in the lower panel. Cell viability data are mean ± SD and are representative from n= 2 biological replicates (n= 4 technical
replicates). MNA cell lines in red; non-MNA cell lines in black. Apoptosis data are mean ± SD (n= 3; two-way ANOVA with Tukey’s multiple comparisons
test). b Cell proliferation of LAN5 RORα Tet-ON cells cultured with (RORα-ON) and without (RORα-OFF) DOX over 8 days. Data are mean ± SD (n= 3;
****p < 0.0001; two-tailed unpaired t-test). Cell cycle analysis of LAN5 RORα-OFF and LAN5 RORα-ON cells following 10 days of DOX (2 µg/ml) induction.
Data are mean ± SD (n= 2). c Left panel: cell growth of LAN5 SiCTRL and LAN5 SiBMAL1 cells in the presence and absence of SR1078 (5 µM) for 4 days.
Data are mean ± SD (n= 3; two-tailed unpaired t-test). Middle panel: Caspase 3/7 activation in LAN5 SiCTRL and LAN5 SiBMAL1 cells following SR1078
treatment (10 µM for 24 h). Data are mean ± SD (n= 3; two-tailed unpaired t-test). Right panel: cell growth of LAN5 RORα SiCTRL and LAN5 RORα
SiBMAL1 cells treated with (+Tet, RORα-ON) and without (−Tet, RORα-OFF) DOX for 4 days. Data are mean ± SD (n= 3, ****p < 0.0001; two-tailed
unpaired t-test). d Left panel: Heat map of differentially expressed genes in LAN5 cells following SR1078 treatment (10 μM for 8 h). Right panel: Most
enriched up- and downregulated pathways by SR1078 in LAN5 cells (p < 0.05). Blue= downregulated genes, red= upregulated genes.
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MYCN-mediated lipogenesis. SCD1 expression is frequently ele-
vated in cancer57 and its inhibition has shown some anti-tumor
activity58. We find that high SCD1 expression predicts poor clinical
outcomes in NB and its expression directly correlates with MYCN
amplification. This could represent a potentially targetable meta-
bolic vulnerability.
Overall, our results demonstrated that restoration of the
molecular clock via activation of RORα blocks MYCN-driven
tumor growth and lipid metabolism (Supplementary Fig. 18).
These novel findings implicate RORα activation as a potential
therapeutic strategy for blocking MYCN-mediated dysregulation
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Methods
Cell lines and culture conditions. SH-SY5Y, IMR32, SK-N-BE(2)-C, SK-N-AS,
NGP (ATCC), LAN5, and CHLA255 (Metelitsa, BCM, Houston, TX), and MYCN3
(Shohet, BCM, Houston, TX) NB cell lines were maintained in RPMI 1640 med-
ium. Tet-21/N (Perini, Bologna, Italy) cells were grown in DMEM high glucose
medium and kept in selection with neomycin (G418, Santa Cruz Biotechnology#
sc-29065a, 0.2 mg/ml) and hygromycin (Sigma Aldrich# H3274, 0.150 mg/ml). All
cell lines were validated by genotyping and regularly tested for mycoplasma. To
turn off MYCN, doxycycline (DOX; Santa Cruz Biotechnology# sc-204734A) was
added at a final concentration of 2 µg/mL. SK-N-AS MYCN-ER (Altman, Roche-
ster, USA) cells were maintained in DMEM high glucose and sodium pyruvate. To
activate MYCN transcription, cells were treated with 1 µM 4-hydroxytamoxifen
(Sigma Aldrich# T176) for 48 h. Cell lines were validated by genotyping and
confirmed by expression of CD56, Nestin, MYCN, and tyrosine hydroxylase within
the past 12 months. SR1078 (Calbiochem# 557352) was used at a concentration of
5–15 μM for in vitro studies. BSA-conjugated oleic acid (Sigma Aldrich# O3008)
was supplemented in the culture media (10–500 µM).
Primary NBs survival data. mRNA gene expression analyses were performed
within R2: a genomics analysis and visualization platform (http://r2.amc.nl), using
datasets: NB Kocak (n= 649, GEO: GSE45547, patient cohort 1), NB Versteeg
(n= 88, GEO: GSE16476 88/122, patient cohort 2), and NB Research Consortium
(NRC; n= 283, GEO: GSE85047, patient cohort 3). In the Kocak dataset, 476 of the
649 samples were annotated with survival data. To test the association of gene
expression with survival, individual gene expression profiles were dichotomized by
a median split into “high” or “low” groups, and Kaplan–Meier survival curves were
plotted for each group. A Cox regression model was used to test for the inde-
pendent predictive ability of RORα expression after adjustment for other significant
factors: MYCN amplification, age, and INSS stages. The Mann–Whitney U test was
used to evaluate the significant differences among quantitative variables. The sig-
nificance of correlation analyses between MYCN and RORα was evaluated by the
Spearman test.
Plasmid constructs. To generate MYCN-inducible MYCN3 cells, MYCN cDNA
was cloned into a pTR2-Hygro vector (BD Biosciences) containing a tetracycline-
responsive promoter. The construct was then transfected into a SHEP sub-clone
stably expressing the tetracycline response element and selected with
hygromycin59. For LAN5 ShMYCN cells, GIPZ human MYCN lentiviral clones
(V2LHS_36755 and V3LHS_322662) were obtained from the Cell-Based Screening
Service core at Baylor College of Medicine (BCM). MYCN–shRNA sequences were
inserted in the lentiviral gene silencing vector pInducer11, which has a dual
fluorescent system consisting of a constitutive cassette (rtTA3 and eGFP) to detect
infection efficiency and a turboRFP (tRFP)-shRNA cassette activated upon DOX
treatment. To generate LAN5 and SK-N-AS RORα conditional overexpressing
cells, RORα isoform 1 cDNA (Origene# RC202926) was cloned into the pENTR/D-
TOPO vector (Invitrogen) and then gateway cloned into a pInducer21 lentiviral
vector with RORα-HA under the control of the tetracycline-inducible promoter.
LAN5 cells were transduced with lentiviral vectors at a multiplicity of infection
sufficient to achieve greater than 90% infection as determined by the presence of
GFP fluorescence. BMAL1 siRNAs (scrambled and BMAL1 targeted) were
obtained from Thermo Scientific (Dharmacon SMARTpool siRNAs, which consists
of a pool of four siRNA sequences, #SO-2564383G). To generate LAN5 Shp53 cells,
second-generation lentiviruses expressing Shp53 and ShLuc control were used as
previously described60. Briefly, 293 T cells were transfected with pLSLPw construct
along with pVSVG and pLV-CMV-delta 8.2 by using lipofectamine. Virus-
containing supernatants were collected at 48 h and 72 h and NB cells transduced in
the presence of 8 mg/ml polybrene (Sigma).
In vitro functional assays. To test the effect of SR1078 on cell viability, 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was carried
out as previously described61. Cell proliferation was assessed using the CCK-8 Kit
(Dojindo, Kumamoto, Japan) according to the manufacturer’s instructions. Briefly,
3–5 × 103 cells/well were seeded in 96-well plates. At determined times, CCK-8
reagent (10 µl) was added to the wells and incubated at 37 °C for 4 h, and absor-
bance (450 nM) was measured. Caspase 3/7-mediated apoptosis was determined
using the Caspase-Glo assay kit (Promega). Briefly, 5 × 103 cells/well were seeded in
96-well plates and subjected to different treatments for 24–48 h. Equal volumes of
caspase reagent were added to the wells, and luminescence was measured in a
plate-reading luminometer after 3 h incubation. Cell cycle distribution was mea-
sured by PI Flow Cytometry Kit (abcam# 139418). LAN5 RORα cells were har-
vested and fixed (70% ethanol for 2 h). Cells were stained with 50 µg/ml PI for 30
min before FACS analysis (BD LSRII with BD FACSDIVA v6.1.3). Cell population
(%) in G0-G1, S, and G2 phases was analyzed by FlowJo v7.6.1.
Real-time q-PCR and western blotting. Total RNA was extracted and purified
with RNeasy kit (QIAGEN). Real-time PCR was performed with SYBR green
reagent using a 50 ng template in a 25 μl reaction mixture according to the man-
ufacturer’s protocol. Levels of GAPDH and CUL1 were used for normalization. All
primers were designed with one primer overlapping an exon boundary. Primer
sequences are listed in Supplementary Table 3. For western blotting analyses, cells
and tumor tissue were lysed with RIPA buffer (Sigma) containing protease inhi-
bitors (Roche). Protein concentration was measured by Bradford assay (Bio-Rad
reagent) and 50–75 μg protein was electrophoresed and transferred. Cyclophilin B
(CypB) was used as the protein loading control. Primary antibodies: MYCN (Cell
Signaling# 9405 S; 1:500 dilution); c-MYC (Abcam# ab32072; 1:500 dilution);
RORα (Santa Cruz Biotechnology# sc-6062; 1:500 dilution); p53 (Santa Cruz
Biotechnology# sc-126; 1:500 dilution); BMAL1 (Cell Signaling# 14020 S; 1:1000
dilution); REV-ERBα (Cell Signaling# 13418 S; 1:500 dilution) and CypB (Santa
Cruz Biotechnology# sc-130626; 1:1000 dilution). Secondary antibodies: anti-
mouse IgG IRDye680RD (Licor# 926-68070; 1:10000 dilution) and anti-rabbit IgG
IRDye800CW (Licor# 926-3211; 1:10000 dilution). Blots were scanned on an
Odyssey infrared imaging system (LI-COR) and analyzed by Odyssey® Application
Software v3.0. Protein expression was quantified by densitometry (ImageJ v1.42q).
All uncropped blot scans are provided in the Source Data file.
RNA-seq analysis. We generated libraries with the Illumina TruSeq Stranded
mRNA (p/n 20020594) kit starting with 150 ng of RNA, and we sequenced with the
NextSeq 500, PE75, v2.5 reagent kit. Differential expression programs from RNA-
seq profiles of LAN5 cells treated with SR1078 (10 μM) for 8 h were identified.
Fastq files were aligned to the reference genome (hg38.p12) using STAR (v2.4) with
default settings to produce transcripts per million (tpm) estimates for each ensembl
gene62. When identifying up- and downregulated genes, we required genes to be
significantly dysregulated by t-test and with a consistent fold change above 1.5 or
below 0.67 compared to controls. Expression values were offset by adding a pseudo
count of 1 tpm for each gene to exclude genes with low expression estimates. Gene
set enrichment for Reactome pathways based on dysregulated genes was performed
in Enrichr63. Pathways in the same category were grouped. Significant genes were
sorted by p-value and associated with pathway terms.
Chromatin immunoprecipitation (ChIP). The MYCN ChIP assays were per-
formed as follows. Briefly, 1 × 107 cells were cross-linked using 1% formaldehyde,
and the reaction was stopped using 0.125 M Glycine. The cell pellet was resus-
pended in cell lysis buffer and following 3500×g centrifugation, RIPA sonication
buffer was added to complete nuclei lysis. DNA shearing was performed by
Fig. 5 SR1078 and RORα genetic overexpression block tumor growth and inhibit lipid metabolism. a Tumor weights (mean ± SD) from MNA LAN5- and
IMR32-derived xenografts treated with vehicle control or SR1078 (15mg/kg i.p. for 14 days) (LAN5: p= 0.02, Mann–Whitney test, control group n= 10
and SR1078 group n= 8; IMR32: p= 0.0004, Mann-Whitney test, control group n= 11 and SR1078 group n= 11). BMAL1 protein expression in
representative LAN5-xenografted tumor lysates from SR1078 treated mice and controls. b Tumor weights (mean ± SD) from non-MNA SK-N-AS derived
xenografts treated with vehicle control or SR1078 (15mg/kg i.p. for 14 days) (p= 0.5116, Mann–Whitney test, control group n= 10 and SR1078 group n=
10). c. Tumor weights (mean ± SD) from DOX-induced (RORα-ON) and controls (RORα-OFF) mice (p= 0.013, Mann–Whitney test, RORα-OFF group n=
6 and RORα-ON group n= 8). BMAL1 protein expression in tumor lysates from representative RORα-ON and RORα-OFF mice. d Heat map and relative
levels of altered DG and TG in LAN5-derived xenografts treated with vehicle control (n= 10) or SR1078 (n= 8; 15mg/kg i.p. for 14 days). Groups were
compared by a two-tailed unpaired t-test. P-values were adjusted by the Benjamini–Hochberg method to obtain FDR. Changes with FDR < 0.25 were
selected for heat map presentation; *=FDR < 0.25. Yellow= upregulated lipids; blue=downregulated lipids. e Heat map and relative levels of altered
intratumoral FAs (*=FDR < 0.25) in LAN5-derived xenografts treated with vehicle control (n= 8) or SR1078 (n= 7; 15 mg/kg i.p. for 14 days). Groups
were compared by a two-tailed unpaired t-test. P-values were adjusted by the Benjamini-Hochberg procedure to obtain FDR. Changes with FDR < 0.25
were selected for heat map presentation; *=FDR < 0.25. AHA aminoheptanoic acid, DDA dodecanoic acid, DG diglycerides, DHA docosahexaenoic acid,
DTA docosatetraenoic acid, EPA eicosapentaenoic acid, ETRA eicosatrienoic acid, HDA hexadecanoic acid, ODA octadecanoic acid (stearic acid), ODCA
octadecenoic acid (oleic acid); TG triglycerides. For panels (d) and (e): the box plot is defined by two lines at the 25th and 75th percentile. A line is drawn
inside the box at the 50th percentile.
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sonication using the Bioruptor PLUS (Diagenode). A small aliquot of sonicated
material was put aside, and the remaining sample was immunoprecipitated using 5
μg of ChIP-grade antibodies (B8.4.B, Santa Cruz Biotechnology# sc-53993). Rec-
sepharose Protein A or G beads (Invitrogen) were used to immobilize immuno-
complexes and RNAse-A treatment (37 °C 1 h) and reverse crosslinking was per-
formed using Proteinase K (Roche) for 6 h at 65 °C. Immunoprecipitated DNA was
purified using phenol/chloroform and ethanol precipitation techniques. DNA was
analyzed by q-PCR and normalized by the fold enrichment method (2−(ΔΔCT))
using the primers listed in Supplementary Table 3. The ABCA10 transcription start
site was used as a negative control DNA region for MYCN. The BMAL1-ChIP
assays were performed using the ChIP-IT® Express Enzymatic (Active Motif#
53009) following the manufacturer’s protocol. Approximately, 1.5 × 107 cells were
fixed using 1% formaldehyde. The fixation reactions were stopped by adding
Glycine Fix-Stop solution. After washing with ice-cold PBS, cells were collected in a
solution containing PMSF and centrifuged at 4 °C. The cell pellet was disrupted
with a Dounce homogenizer in 1 ml ice-cold lysis buffer containing protease











SK-N-AS MYCN-ER RORα Tet-ON
ACACA
c










































































































































































MYCN ChIP - Tet
Input - Tet
Input + Tet

















p = 8.276 e-12






























ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-24196-4
12 NATURE COMMUNICATIONS |         (2021) 12:4006 | https://doi.org/10.1038/s41467-021-24196-4 | www.nature.com/naturecommunications
inhibitor and PMSF. After centrifugation, nuclei were resuspended in digestion
buffer containing protease inhibitor and PMSF, then incubated at 37 °C for 5 min.
Chromatin was then sheared to 200–300 bp by adding an enzymatic shearing
cocktail for 10 min at 37 °C. Samples were centrifuged at 21,000xg for 10 min at
4 °C. One percent aliquot of this material was retained as “input” DNA. The
remaining chromatin sample was divided, one-half was immunoprecipitated with
the BMAL1 antibody (Abcam# 93806), and the second half was used for a mock
immunoprecipitation with a control IgG. Real-time PCR amplification was carried
out using 2.5 μl of DNA sample, using primers listed in Supplementary Table 3.
Circadian oscillation studies. Real-time bioluminescence monitoring: MYCN3 and
LAN5 cells were treated with or without 1 μg/ml DOX for 48 h before infection
with Per2-dluc adenovirus as previously described64 for another 24 h. Cells were
then serum shocked with 50% horse serum for 30 min before being subjected to
real-time bioluminescence as previously described32. BMAL1 circadian oscillation:
SK-N-AS MYCN-ER RORα cells were cultured with and without 4OHT (MYCN-
ON/OFF), DOX (RORα-ON/OFF), and 4OHT+DOX for 24 h and then syn-
chronized with 50% horse serum for 2 h. Cells were collected every 6 h from 16 to
64 h after synchronization. 4-OHT and DOX treatments were applied during and
after cell synchronization. BMAL1 mRNA expression was determined by q-PCR
and normalized to 18 S expression. To test for rhythmicity, JTK_Cycle65 was
applied. For serum shock experiments, rhythmicity was determined from all values
excluding the ZT0 (unsynchronized) time point.
FA measurement. FA tracing was performed using pentafluorobenzyl bromide
(PFBBr) derivatization and GC-MS negative chemical ionization as previously
described66. SP-2380 columns (Supelco, Inc.) were used to allow better peak
separation of palmitoleic from sapienic acid. Data were acquired in selective ion
monitoring mode. The fragment masses m/z of 227–229 were used to monitor
M0–M2 in myristic acid; 255–257 and 271 for M0–M2 and M16 in palmitic acid; and
253–255 and 269 for M0–M2 and M16 in palmitoleic acid. Analyte and standards
peak areas were determined. The ratio of the area from the sum (M0–M2) analyte-
derived ions compared to that from the tridecanoic acid (C13:0) (m/z, 213–215)
internal standard was calculated. The ratios were then compared with the cali-
bration curves to determine the concentration of each FA. To determine de novo
lipogenesis, deuterated water (D2O) (atom 99%, Cambridge Isotope Laboratory)
was added to the media to reach an enrichment of 2.5%. The percentage con-
tribution of newly made FA was calculated as total 2H-labeled FA/(2H-labeled body
water × n) × 100 (n= number of exchangeable hydrogens). Total 2H-labeled FA
was calculated as EM1 × 1+ EM2 × 2, where E is the enrichment of the isotopomer.
The absolute amount of newly synthesized FA was determined as the percentage of
newly made FA × the concentration of the total FA. The FA amount was then
normalized by the protein content of each sample. For desaturase activity mea-
surement, [U-13C] palmitic acid (99 atom%13C, Cambridge Isotope Laboratories)
was added (1.0 mg/100 mL) to the incubation media and D2O mix. The con-
centration of [13C16] in palmitic or palmitoleic acid was calculated as the area of
M16/sum area (M0–M2) × the concentration of FA. Desaturase activity was mea-
sured as the ratio of [13C16] palmitoleic acid to [13C16] palmitic.
In vivo, FA profiling was performed using high-performance liquid
chromatography (HPLC) coupled to Agilent 6495 QQQ mass spectrometry
(Agilent Technologies) using ESI negative ionization via single reaction
monitoring. FAs were extracted as previously described67. Separation was
performed on a Luna 3u phenyl-hexyl column (150 × 2 mm) using 10 mM
ammonium acetate pH 8 (mobile phase A) and methanol (mobile phase B). The
binary pump flow rate was 0.2 ml/min with a gradient starting at 40% B at 0 min,
50% at 8 min, 67% at 13 min, 100% at 23 min, and 40% at 30 min to the initial
condition and re-equilibration till the end of the gradient at 37 min. Data were
analyzed with Agilent mass hunter quantitative software (v10.0) and were
normalized with an internal standard and log2 transformed per sample. For every
FA in the normalized dataset, two-sample t-tests were conducted to compare
expression levels between different groups. Differential metabolites were identified
by adjusting the p-values for multiple testing at FDR < 0.25.
In vivo studies. In vivo studies were approved by the Institutional Animal Care and
Use Committee of BCM (AN7089). Orthotopic xenografts of human NB were gen-
erated as previously described40. Briefly, an inoculum of 106 tumor cells in 0.1 mL of
PBS was injected under the renal capsule of 4–6-week-old female athymic Ncr nude
mice (Taconic). Two weeks after cell implantation and confirmation of successful
tumor engraftment by bioluminescent imaging (Xenogen IVIS 100 System, Caliper
Life Sciences), mice were randomized and divided into treatment groups. Four to five
weeks post-implantation mice were sacrificed, tumors resected, weighed, and pre-
served in 4% paraformaldehyde for immunohistochemical analysis. All animal data
were compared using the Mann–Whitney test. To induce RORα expression DOX
Hyclate (Sigma Aldrich# D9891) was given as an intraperitoneal injection (5mg/kg)
at day −1, 0, and +1 post-implantation and weekly for three weeks. DOX (2mg/ml)
was then supplemented in 5% sucrose drinking water. SR1078 (Calbiochem# 557352)
was administered i.p. daily (15mg–25mg/kg in DMSO). Etoposide (VP16, Sigma
Aldrich# E1383) was administered i.p. three times a week (15mg/kg in DMSO)
for two weeks. Vehicle control (PBS, PEG (5.4%) Tween 20 (5.4%), DMSO (4%))
was administered i.p. daily. Combination therapy of VP16 (10mg/kg) and SR1078
(25mg/kg) was administered i.p. daily for two weeks. Immunohistochemistry staining:
Assessment of tumor cell proliferation and apoptosis was performed as previously
described68. Briefly, paraffin-embedded tumor sections were blocked with horse
serum (10%) and incubated with Ki67 antibody (BD Bioscences# 550609; 1:400
dilution) or cleaved caspase 3 antibody (Cell Signaling# 9661 L; 1:400 dilution) at 4 °C
overnight. Sections were washed with PBS and incubated with biotinylated anti-
mouse (BA# 9200; 1:200 dilution) and anti-rabbit (BA# 1000; 1:200 dilution) anti-
bodies at room temperature for 30min, following incubation with the 3,3′-diami-
nobenzidine solution and counterstaining with hematoxylin. For tumor section
scoring, four fields were evaluated with 500 tumor cells in each field using light
microscopy, and percent positive tumor cells were calculated.
Lipidomics. Sample Preparation was as follows: Tumor samples were homogenized
with an equal ratio of 0.15 M KCl and methanol followed by 400 µL of dichlor-
omethane and 2 µL of acetic acid. Internal standards and quality control samples
were prepared as previously described69. Briefly, an equimolar concentration of 10
µL of internal standards was added to each sample before adding water and
dichloromethane (1:1). After centrifugation (5 min 6500×g), the lower organic layer
was collected and dried under nitrogen. Before mass spectrometric (MS) analysis,
the dried extract was suspended in 100 μL of solution (10:5:85 acetonitrile/water/
isopropyl alcohol containing 10 mM ammonium acetate) and subjected to liquid
chromatography/triple time-of-flight (TOF) for analysis (Shimadzu CTO-20A
Nexera X2 41 UHPLC system). MS analysis was carried out on a Triple TOF 5600
equipped with Turbo VTM ion source (AB Sciex). Data were acquired with Analyst
TF software v1.8 (AB Sciex). Lipids were separated on the acquity HSS UPLC T3
column (Waters) at 55 °C. The initial mobile phase consists of acetonitrile/water
(40:60 v/v) with 10 mM ammonium acetate, and acetonitrile/water/isopropanol
(10:5:85 v/v) with 10 mM ammonium acetate with gradient elution at a flow rate of
0.4 mL/min and an injection volume of 5 μL. Operating source conditions for
Triple TOF scan for positive ionization: source voltage 5500 V, declustering
potential (DP) 60 V, source T 450 °C, ion source gas 1 (GS1) 40 psi, ion source gas
2 (GS2) 45 psi, curtain gas (CUR) 30 psi, and collision energy 10 V. Conditions for
negative ionization: source voltage −4500V, DP 60 V, GS1 40 psi, GS2 45 psi, CUR
30 psi, and collision −10 V. The MS/MS spectra were controlled by data-dependent
Fig. 6 SR1078 opposes MYCN-induced lipogenesis. a Left panel: schematic representation of the main enzymatic steps of de novo lipogenesis. Right
panel: MYCN ChIP assays in LAN5 cells (input=white bars; MYCN IP= blue bars). Samples were analyzed by q-PCR using specific primers for lipogenic
enzymes (ACACA, FASN, and SCD1). RORc served as negative control (Supplementary Table 3). Data are mean ± SD (n= 3 biological replicates; ****p <
0.0001; two-tailed unpaired t-test). bmRNA expression of lipogenic enzymes in LAN5 SiCTRL and SiBMAL1 cells upon SR1078 treatment (10 µM for 24 h).
Data are mean ± SD (n= 3; ****p < 0.0001; two-tailed unpaired t-test). c BMAL1 ChIP-qPCR assays in SK-N-AS MYCN-ER RORα cells following 4OHT (1
µM for 24 h), DOX (2 µM for 24 h), and 4OHT+DOX treatments. Data are mean ± SD (n= 3; two-tailed unpaired t-test). dmRNA expression of lipogenic
enzymes in MYCN3 (MYCN-ON) cells upon SR1078 treatment (10 µM for 24 h). Data are mean ± SD (n= 3; ****p < 0.0001; one-way ANOVA with
Dunnett’s multiple comparisons test). e Determination of de novo lipogenesis and SCD1 activity in MYCN3 (MYCN-ON) cells upon SR1078 treatment
(5 µM for 72 h). Data are mean ± SD (n= 4 biological replicates; ****p < 0.0001; one-way ANOVA with Dunnett’s multiple comparisons test).
f Kaplan–Meier analysis of overall survival (OS) and event-free survival (EFS) in the NB NRC patient cohort (n = 101) based on SCD1 mRNA expression.
Significant (p= 8.276 E−12 by Fisher’s exact test) association with MYCN amplification is shown. g MYCN ChIP assays in Tet-21/N cells in conditions of
MYCN-ON and MYCN-OFF (DOX for 48 h) (input=white bars; MYCN IP= blue bars). Samples were analyzed by q-PCR using specific primers for SCD1
and RORc (Supplementary Table 3). Data are mean ± SD (n= 3 biological replicates; two-tailed unpaired t-test). h Cell viability of LAN5 cells treated with
SR1078 (10 μM for 48 h) in control (CTRL) media (0.3 mM BSA) or CTRL media supplemented with oleic acid (500 μM for 48 h). Data are mean ± SD
(n= 3 biological replicates; one-way ANOVA with Dunnett’s multiple comparisons test). Representative images (100×) of LAN5 cells; scale bar=50 µM.
FC fold change, FE fold enrichment.
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acquisition with dynamic background subtraction, charge monitoring, and
dynamic exclusion of former target ions for 9 s. Rolling collision energy spread was
set to generate a collision energy ramp around a collision energy center point with
the goal of providing a richer MS/MS spectrum of lipids. Mass accuracy was
maintained by the use of an automated calibrant delivery system interfaced to the
second inlet of the DuoSpray source. Data processing and statistical analysis were
performed as previously described67. Briefly, data were normalized by median
inter-quantile range normalization and were log2 transformed. The two groups
were compared by Student’s t-test. P-values were adjusted by the
Benjamini–Hochberg procedure to obtain FDR. Changes with FDR < 0.25 were
selected for heat map presentation.
Statistical analysis. Data were collected in Microsoft Excel 2013 and analyzed in
GraphPad Prism v7. All in vitro assays are expressed as mean ± standard deviation
(SD) and performed in triplicate. Data are compared using a two-sided unpaired t-
test, one or two-way ANOVA with Tukey’s, Sidak’s, and Dunnett’s multiple
comparisons test. Tumor weights are expressed as mean ± SD and compared using
Mann-Whitney tests; p-values < 0.05 were considered statistically significant.
Rhythmicity was tested using the non-parametric test, JTK_Cycle, R version 4.0.3,
package MetaCycle.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Publicly available clinical datasets GSE45547, GSE16476, and GSE85047. were analyzed
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Fig. 7 SR1078 sensitizes NB to conventional chemotherapy. a Cell viability (72 h) and caspase 3/7 activation (24 h) of MNA cells (LAN5, IMR32, and
NGP) upon treatment with SR1078, etoposide (VP16), and their combination. Cell viability data are means and are representative from n= 2 biological
replicates (n= 4 technical replicates). Apoptosis data (SR1078 2.5 μM; VP16 100–200 nM) are means ± SD (n= 3; ****p < 0.0001; one-way ANOVA with
Tukey’s multiple comparisons test). b Tumor weights (mean ± SD) from NGP-derived xenografts treated with vehicle control, SR1078 (20mg/kg i.p. daily),
VP16 (10mg/kg i.p. 3 times/week), and their combination (in red). All treatments continued for 14 days (Mann–Whitney test; control group n= 6; SR1078
group n= 9; VP16 group n= 5; combination group n= 8).
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sequencing data generated in this study have been deposited in the European Nucleotide
Archive (ENA, https://www.ebi.ac.uk/ena/), accession number: PRJEB36158. All Figures
and Supplementary Figures have associated raw data. Raw data of Figs. 1–7 and
Supplementary Fig. 1–18, and uncropped blots are provided as one Source Data file. All
the other data are available within the article and its Supplementary Information. Source
data are provided with this paper.
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